secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K/A
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001831868-25-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.01, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical Q2 net loss $2.0M on $0.3M revenue; NEUTRALIZE-AKI trial 60% enrolled
--------------------------------------------------------------------------------

- Net loss of $2.0M ($0.18/share) vs $3.2M ($1.03/share) in Q2 2024; revenue from QUELIMMUNE pediatric SCD was $0.3M.
- NEUTRALIZE-AKI pivotal trial enrollment reached 125 of 200 patients (60%+); interim DSMB recommendations expected Q3 2025.
- Added three new top children's hospital customers; SAVE Surveillance Registry showed 75% 28-day survival in first 20 patients.
- Raised total $20.8M through offerings in June ($12.4M), July and August 2025 ($8.4M) to extend cash runway into 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000183186825000011/0001831868-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000183186825000011/icu-20250813.htm
  HTML page:      https://secwatch.observer/filing/0001831868-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer